Printer Friendly

Belgium : Commission approves acquisition of Abbott Laboratories' Non-U.S. Developed Markets Specialty and Branded Generics Business by Mylan, subject to conditions.

The European Commission has cleared under the EU Merger Regulation the proposed acquisition of Abbott Laboratories' Non-U.S. Developed Markets Specialty and Branded Generics Business ("Abbott EPD-DM"), by Mylan, Inc ("Mylan"). Abbott EPD-DM is a Swiss-based manufacturer focused on distributing branded ex-originator products with expired patents and with internal production capabilities in Europe, Canada and Japan. Mylan is a US-based producer of generic pharmaceuticals. The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy. The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns.

The Commission examined the effects of the proposed transaction on competition in particular in five therapeutic areas, namely cardio-metabolic, gastro, anti-infective / respiratory, central nervous system / pain and women's and men's health.

The Commission's investigation found that for the majority of the products no competition concerns arise. However, for five products in certain geographic areas the Commission's market investigation identified concerns, in particular, because of the lack of substitutable products, high combined market shares of the Parties on narrow markets, few competitors present and low likelihood of entry. The markets where the Commission identified potential competition concerns are those for mebeverine in Germany and in the United Kingdom, pygeum africanum in France, betahistine in Ireland, and delorazepam in Italy.

To address these concerns, Mylan offered to divest its local businesses in the concerned markets, including the relevant marketing authorizations, customer information and supply contracts.

This commitments package will remove the competition concerns identified by the Commission.

The Commission therefore concluded that, in light of the proposed commitments, the transaction would no longer raise competition concerns. This decision is conditional upon full compliance with the commitments.

The transaction was notified to the Commission on 18 November 2014.

2014 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jan 30, 2015
Previous Article:Belgium : Commission approves acquisition of GSK's oncology business by Novartis, subject to conditions.
Next Article:Belgium : Agfa Graphics with automatic board feeder and varnish printing at C!Print in Lyon (FR).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters